Skip to main content

OriGene Technologies Raises $16M

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – OriGene Technologies has raised $16 million in a Series B financing led by IDG-Accel, SBI & TH Venture Capital Enterprise, and Zero2IPO, the firm said yesterday.

The Rockville, Md.-based genetic tools company said that previous investors Morningside Venture Investments and President International Development also participated in the round.

OriGene intends to use the funds to help build its TrueMAB monoclonal antibody collection with an aim of covering the majority of the human proteome. Among the firms other products are cDNA and shRNA clone collections; over 5,000 purified human proteins; 100,000 highly validated human tissues; and assay products based on Luminex's multiplex platform.

"The funding will propel us closer to meeting our goal of building the largest monoclonal antibody collection in the world covering the entire human genome of approximately 20,000 genes," Wei-Wu He, OriGene's chairman and CEO, said in a statement.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.